Belatacept in renal transplantation-quo vadis?

Of note, the combined end point graft loss and mortality reached significance after 7 years, mortality alone tended to be substantially lower as well (hazard ratio for death 0.55 for approved dosing scheme) but did not reach statistical significance (P=0.06).

also in 111,027 other papers